Pokaż cały numer - FPN - Farmaceutyczny PrzeglÄ d Naukowy

copyright © 2010 Grupa dr. A. R. Kwiecińskiego ISSN 1425-5073
Piśmiennictwo
1. Nowak M i wsp. Regulacyjna rola białek inhibitorowych
apoptozy (IAP). Farm Przegl Nauk 2010; 8: 32-37.
2. Perrelet D i wsp. IAP family proteins delay motoneuron
cell death in vivo. Eur J Neurosci 2000; 12: 2059–
2067.
3. Kugler S i wsp. The X-linked inhibitor of apoptosis
(XIAP) prevents cell death in axotomized CNS neurons
in vivo. Cell Death Differ 2000; 7: 815–824.
4. Crocker SJ i wsp. NAIP protects nigrostriatal dopamine
pathway in an intrastriatal 6-OHDA rat model of Parkinson’s
disease. Eur J Neurosci 2001; 14: 391– 400.
5. Sasaki H i wsp. Down-regulation of X-linked inhibitor
of apoptosis protein induces apoptosis in chemoresistant
human ovarian cancer cells. Cancer Res 2000; 60:
5659–5666.
6. Holcik M i wsp. Translational upregulation of X-linked
inhibitor of apoptosis (XIAP) increases resistance to radiation
induced cell. Heath Oncogene 2000; 19: 4174-4177.
7. Dai Z i wsp. A comprehensive search for DNA amplification
in lung cancer identifies inhibitors of apoptosis
cIAP1 and cIAP2 as candidate oncogenes. Hum Mol
Genet 2003; 12: 791–801.
8. LaCasse EC, Mahoney DJ, Cheung HH. IAP-thargeted
therapies for cancer. Oncogene 2008; 27: 6252-6275.
9. Jansen B, Zangemeister-Wittke U. Antisense therapy
forcancer––the time of truth. The Lancet 2002; 3:
672–683.
10. Lima RT i wsp. Special downregulation of bcl-2 and
xIAP by RNAi enhances the effects of chemotherapeutic
agents in MCF-7 humanbreast cancer cells. Cancer
Gene Ther 2004; 11: 309–316.
11. McManus DC i wsp. Loss of XIAP protein expression
by RNAi and antisense approaches sensitizes cancer
cells to functionally diverse chemotherapeutics. Oncogene
2004; 23: 8105–8117.
12. Amantana A i wsp. X-linked inhibitor of apoptosis protein
inhibition induces apoptosis and enhances chemotherapy
sensitivity in human prostate cancer cells. Mol
Cancer Ther 2004; 3: 699–707.
13. Danson S i wsp. IAPs as a target for anticancer therapy.
Curr Cancer Drug Targets 2007; 7: 785–794.
14. Brennan DJ i wsp. Altered cytoplasmic-to-nuclear ratio
of survivin is a prognostic indicator in breast cancer.
Clin Cancer Res 2008; 14: 2681–2689.
15. Varfolomeev E i wsp. IAP antagonists induce autoubiquitination
of c-IAPs, NF-kappaB activation, and TNFalpha-
dependent apoptosis. Cell 2007; 131: 669–681.
16. Mahoney DJ i wsp. Both cIAP1 and cIAP2 regulate
TNF alpha-mediated NF-kB activation. Proc Natl Acad
Sci USA 2008;105: 11778–11783.
17. Cillessen SA i wsp. Small-molecule XIAP antagonist
restores caspase-9 mediated apoptosis in XIAP-positive
diffuse large B-cell lymphoma cells. Blood 2008; 111:
369–375.
18. Chen J i wsp. Design, synthesis, and characterization
of new embelin derivatives as potent inhibitors of X-
linked inhibitor of apoptosis protein. Bioorg Med Chem
Lett 2006; 16: 5805–5808.
19. Obiol-Pardo C, Granadino-Roldan JM, Rubio-Martinez
J. Protein–protein recognition as a first step towards the
inhibition of XIAP and Survivin anti-apoptotic proteins.
J Mol Recognit 2008; 21: 190–204.
20. Bauvois B, Dauzonne D. Aminopeptidase-N/CD13
(EC 3.4.11.2) inhibitors: chemistry, biological evaluations,
and therapeutic prospects. Med Res Rev 2006;
26: 88–130.
21. Sato S i wsp. Demonstration of direct binding of cIAP1
degradation-promoting bestatin analogs to BIR3 domain:
synthesis and application of fluorescent bestatin ester
analogs. Bioorg Med Chem Lett 2008; 18: 3354–3358.
22. Altieri DC. Survivin, cancer networks and pathway-directed
drug discovery. Nat Rev Cancer 2008; 8: 61–70.
23. Huang RC, Chang CC, Mold D. Survivin-dependent
and independent pathways and the induction of cancer
cell death by tetra-O-methyl nordihydroguaiaretic acid.
Semin Oncol 2006; 33: 479–485.
24. Plescia J i wsp. Rational design of shepherdin, a novel
anticancer agent. Cancer Cell 2005; 7: 457–468.
25. Meli M i wsp. Small-molecule targeting of heat shock
protein 90 chaperone function: rational identification
of a new anticancer lead. J Med Chem 2006; 49:
7721–7730.
26. Towler MC, Hardie DG. AMP-activated protein kinase
in metabolic control and insulin signaling. Circ Res
2007; 100: 328–341.
27. O’Connor DS i wsp. Regulation of apoptosis at cell
division by p34cdc2 phosphorylation of survivin. Proc
Natl Acad Sci USA 2000; 24: 13103–13107.
28. Mesri M i wsp. Cancer gene therapy using a survivin
mutant adenovirus. J Clin Invest 2001; 108: 981–990.
data otrzymania pracy: 27.09.2010 r.
data akceptacji do druku: 28.10.2010 r.
Adres do korespondencji:
Marcin T. Nowak
ul. Wyspiańskiego 21
43-300 Bielsko-Biała
Tel. +48 602 558-301
e-mail: info@proktomed.pl
13